Pliant Therapeutics (PLRX) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for Pliant Therapeutics (PLRX) over the last 6 years, with Q3 2025 value amounting to -$26.3 million.
- Pliant Therapeutics' Net Income towards Common Stockholders rose 5446.74% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$175.5 million, marking a year-over-year increase of 1298.19%. This contributed to the annual value of -$210.3 million for FY2024, which is 3035.16% down from last year.
- According to the latest figures from Q3 2025, Pliant Therapeutics' Net Income towards Common Stockholders is -$26.3 million, which was up 5446.74% from -$43.3 million recorded in Q2 2025.
- In the past 5 years, Pliant Therapeutics' Net Income towards Common Stockholders ranged from a high of -$22.8 million in Q2 2021 and a low of -$57.8 million during Q3 2024
- In the last 5 years, Pliant Therapeutics' Net Income towards Common Stockholders had a median value of -$37.5 million in 2023 and averaged -$37.8 million.
- Per our database at Business Quant, Pliant Therapeutics' Net Income towards Common Stockholders plummeted by 6357.2% in 2021 and then surged by 5446.74% in 2025.
- Pliant Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$24.5 million in 2021, then tumbled by 42.92% to -$35.1 million in 2022, then decreased by 17.25% to -$41.1 million in 2023, then dropped by 20.98% to -$49.7 million in 2024, then surged by 47.11% to -$26.3 million in 2025.
- Its last three reported values are -$26.3 million in Q3 2025, -$43.3 million for Q2 2025, and -$56.2 million during Q1 2025.